Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase i/ii trials

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
9 Downloads (Pure)


Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if un-treated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact that mesothelioma is a tumor with an “immune desert” phenotype, meaning a non-inflamed tumor characterized by low T-cell infiltration. By administration of DCs, which were ex-vivo cultured, exposed to (tumor-associated) antigens, and subsequently activated, this “immune desert” phenotype might be turned into an “inflamed” phenotype. Three phase I/II studies have been performed and published using activated DCs, which support this concept. We here report on the long-term survival of patients treated with DCs in three phase I/II studies. Methods: Survival data of the phase I/II trials using DC therapy in MPM patients were obtained and subsequently analyzed. In the first two trials, DCs were loaded with autologous tumor lysate. In the third trial, DCs were loaded with allogeneic mesothelioma tumor cell line lysate. Results: In the three studies combined, 29 patients with MPM were treated with DC vaccination between 2006 and 2015. At data cut-off, the median OS was 27 months (95% CI: 21–47 months). OS at 2 years was 55.2% (95% CI: 39.7–76.6%), and OS at 5 years was 20.7% (95% CI: 10.1–42.2%). Conclusions: The long-term survival of DC therapy in MPM in these three trials is promising, which is the basis for the randomized phase II/III DENIM study. This DENIM study is currently enrolling, and the results of which have to be awaited for definite conclusions.

Original languageEnglish
Article number525
Issue number5
Publication statusPublished - 19 May 2021

Bibliographical note

Funding Information:
D.W.D. reports receiving personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Pfizer, personal fees from Astra Zeneca, personal fees from Novartis, outside the submitted work. R.C. reports receiving personal fees from MSD, Spectrum and Roche (served on the advisory board), and personal fees from Bristol Myers Squibb, Pfizer, and Roche (served on the speaker?s bureau). K.B. is employed by Amphera BV. S.J.B.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase i/ii trials'. Together they form a unique fingerprint.

Cite this